Efficacy of AposTherapy® in Knee OA

A Prospective, Randomized Double-Armed Efficacy Evaluation of AposTherapy® for the Treatment of Knee Osteoarthritis

A prospective, interventional, randomized, double-arm clinical evaluation study to examine the efficacy of AposTherapy® versus a control group, in the short-term at 6 months and in the long-term at 12 months post-treatment, with the primary efficacy assessment based on improvement in knee pain score and improvement in function in patients following diagnosis of knee osteoarthritis (OA).

Inclusion Criteria:

• Patients suffering from symptomatic unilateral or bilateral knee OA at the medial compartment for at least six months;
• Fulfilling the ACR clinical criteria;
• Having radiographically assessed OA of the knee with a Kellgren-Lawrence grade more than or equal to grade 2; and,
• Having VAS-Pain ≥ 3, on a scale between 0-10.
• Patients who have a shoe size between US 4 and US 12

Exclusion Criteria:

• Patients suffering from acute septic arthritis.
• Patients who received a corticosteroid injection within 3 months of the study.
• Patients who received hyaluronic acid (HA) injections within 6 months of the study
• Patients suffering from avascular necrosis of the knee.
• Patients with a history of knee buckling or recent knee injury.
• Patients who have had a joint replacement or other major surgery to the knee, hip or ankle (ipsilateral or contralateral side).
• Patients suffering from neuropathic arthropathy.
• Patients with an increased tendency to fall.
• Patients exhibiting a lack of physical or mental ability to perform or comply with the study procedure.
• Patients with a history of pathological osteoporotic fracture.
• Patients suffering from symptomatic degenerative arthritis in lower limb joints other than the knees.
• Patients with referred pain in the knees from primary back or hip joint pain.
• Patients with neurological deficits to the lower extremity (ex. foot drop)
• Patients whose shoe size is less than US 4 and greater than US 12
• Patients who have had arthroscopy within 6 months of the study
• Patients with inflammatory arthropathy